Henning Schade, MD

• Acute Myeloid Leukemia

At The Colorado Blood Cancer Institute he developed an investigator initiated a phase 1 protocol for patients with chemotherapy-refractory AML/MDS using GVHD prophylaxis with posttransplant cyclophosphamide followed by PD-1 inhibition with Nivolumab for consolidation. This protocol now offers a potentially curative treatment option for patients that otherwise would not meet criteria to undergo allogenic stem cell transplantation.